CompanyCUENasdaqBoston, MA

Cue Biopharma, Inc.

Cue Biopharma develops therapies for immunological disorders using its Immuno-STAT platform to target disease-specific T cells.

SEC EDGAR ClinicalTrials.gov cuebio.com

DEF 14ASep 28Latest SEC filing

Sep 21Latest story

September 2026

Cue Biopharma's 8-K confirms Phase 2 CUE-221 data in chronic hives, outlines next steps

Sep 21Clinical readoutCue Biopharma, Inc.

August 2026

Cue Biopharma reports Q2 2026 results, IND filing for CUE-221, $50M PIPE

Aug 14Quarterly updateCue Biopharma, Inc.

Cue Biopharma names James Ahlers as chief financial officer

Aug 3PeopleCue Biopharma, Inc.

July 2026

Cue Biopharma discloses $49.99 million private securities offering

Jul 22FinancingCue Biopharma, Inc.

Cue Biopharma raises $50 million in private placement of stock and warrants

Jul 10FinancingCue Biopharma, Inc.